» Articles » PMID: 22453243

Natural History of Merkel Cell Carcinoma Following Locoregional Recurrence

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2012 Mar 29
PMID 22453243
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with an ill-defined natural history following locoregional recurrence.

Methods: This is a retrospective review of patients with MCC diagnosed at the Mayo Clinic from 1981 to 2008. For each outcome (subsequent locoregional recurrence, distant recurrence, and death) the survival-free of the outcome was estimated using the Kaplan-Meier method. Associations of patient and clinical characteristics with the outcomes were assessed by fitting Cox proportional hazards regression models.

Results: Among the 240 patients diagnosed with MCC, 70 (29%) patients were identified who developed locoregional recurrence as the first site of recurrence. The median time from diagnosis to locoregional recurrence was 6 months. The pattern of first locoregional failure in this group includes 25 (10.4%) local, 18 (7.5%) in-transit, and 27 (11.3%) nodal recurrences. Recurrences were most commonly treated by surgery and radiation. At 3 years after the initial recurrence, locoregional recurrence-free survival was 75% and the distant recurrence-free survival was 56%. Locoregional recurrence is a poor prognostic sign associated with a 3-year overall survival of 39%. Nodal status at time of original surgery and time to first recurrence were important predictors of distant recurrence (P < 0.006) and overall survival following locoregional recurrence (P < 0.001).

Conclusions: Locoregional recurrence is a substantial problem in patients with MCC and is a poor prognostic sign. In those patients who experience a locoregional recurrence, aggressive efforts to regain locoregional control appear warranted and may result in long-term survival.

Citing Articles

Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Lugowska I, Becker J, Ascierto P, Veness M, Blom A, Lebbe C ESMO Open. 2024; 9(5):102977.

PMID: 38796285 PMC: 11145756. DOI: 10.1016/j.esmoop.2024.102977.


Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives.

Zaggana E, Konstantinou M, Krasagakis G, de Bree E, Kalpakis K, Mavroudis D Cancers (Basel). 2023; 15(1).

PMID: 36612102 PMC: 9817518. DOI: 10.3390/cancers15010103.


F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma.

Mahajan S, Barker C, Mauguen A, DAngelo S, Yeh R, Pandit-Taskar N J Nucl Med. 2021; 63(6):906-911.

PMID: 34620729 PMC: 9157731. DOI: 10.2967/jnumed.121.262882.


Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival.

Cook M, Baker K, Redman M, Lachance K, Nguyen M, Parvathaneni U Am J Clin Oncol. 2018; 42(1):82-88.

PMID: 30211723 PMC: 8666386. DOI: 10.1097/COC.0000000000000482.


Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma.

Tseng Y, Nguyen M, Baker K, Cook M, Redman M, Lachance K Int J Radiat Oncol Biol Phys. 2018; 102(2):330-339.

PMID: 30191867 PMC: 9592535. DOI: 10.1016/j.ijrobp.2018.05.075.